Multiple comparisons after ANOVA(CR10). by Xinyu Dai (5100731)

“…Post hoc analysis demonstrated significantly decreased HbO₂ in both the IMW (<i>p</i> = 0.019) and placebo (<i>p</i> = 0.035) groups relative to blank controls. …”

Homogeneity test of CR10. by Xinyu Dai (5100731)

“…Post hoc analysis demonstrated significantly decreased HbO₂ in both the IMW (<i>p</i> = 0.019) and placebo (<i>p</i> = 0.035) groups relative to blank controls. …”

Illustration of the fNIRS device worn. by Xinyu Dai (5100731)

“…Post hoc analysis demonstrated significantly decreased HbO₂ in both the IMW (<i>p</i> = 0.019) and placebo (<i>p</i> = 0.035) groups relative to blank controls. …”

Analysis of variance of HbO₂ in bilateral PFC. by Xinyu Dai (5100731)

“…Post hoc analysis demonstrated significantly decreased HbO₂ in both the IMW (<i>p</i> = 0.019) and placebo (<i>p</i> = 0.035) groups relative to blank controls. …”

fNIRS equipment coordinates. by Xinyu Dai (5100731)

“…Post hoc analysis demonstrated significantly decreased HbO₂ in both the IMW (<i>p</i> = 0.019) and placebo (<i>p</i> = 0.035) groups relative to blank controls. …”

Changes of muscle oxygen saturation. by Xinyu Dai (5100731)

“…Post hoc analysis demonstrated significantly decreased HbO₂ in both the IMW (<i>p</i> = 0.019) and placebo (<i>p</i> = 0.035) groups relative to blank controls. …”

Analysis of variance of CR10. by Xinyu Dai (5100731)

“…Post hoc analysis demonstrated significantly decreased HbO₂ in both the IMW (<i>p</i> = 0.019) and placebo (<i>p</i> = 0.035) groups relative to blank controls. …”

Placement on the forehead. by Xinyu Dai (5100731)

“…Post hoc analysis demonstrated significantly decreased HbO₂ in both the IMW (<i>p</i> = 0.019) and placebo (<i>p</i> = 0.035) groups relative to blank controls. …”

IMW intervention plan design. by Xinyu Dai (5100731)

“…Post hoc analysis demonstrated significantly decreased HbO₂ in both the IMW (<i>p</i> = 0.019) and placebo (<i>p</i> = 0.035) groups relative to blank controls. …”

Flowchart of the study population. by Alejandro Rojas Chaves (20614814)

Subjects:

Univariate analyses. by Zachary E. M. Giovannini-Green (22008277)

“…Female individuals and rural residents also had significantly higher mean monthly ED visits than male individuals (Female = 0.51 vs Male = 0.21, p < 0.01) and urban residents (rural = 0.38 vs urban = 0.21, p = 0.02). …”

Overview of individuals in the study. by Zachary E. M. Giovannini-Green (22008277)

“…Female individuals and rural residents also had significantly higher mean monthly ED visits than male individuals (Female = 0.51 vs Male = 0.21, p < 0.01) and urban residents (rural = 0.38 vs urban = 0.21, p = 0.02). …”

Multivariate analyses. by Zachary E. M. Giovannini-Green (22008277)

“…Female individuals and rural residents also had significantly higher mean monthly ED visits than male individuals (Female = 0.51 vs Male = 0.21, p < 0.01) and urban residents (rural = 0.38 vs urban = 0.21, p = 0.02). …”

Linear mixed model results, fixed effects for time points, group, time points x group and univariate effects in the two groups WAD grades 2 and 3. by Anneli Peolsson (7867601)

Results of redundancy analysis. by Bianhua Zhang (22430652)

“…All the heavy metal contents in MLS were highest significantly except Cd among NL and LFA. Shannon and Chao1 indices in NC were significantly higher than those in MC (p < 0.05), In LFA, Shannon and Chao1 indices of MLX were the highest, while MLS was significantly lower than NL (p < 0.05). …”

S1 File - by Natalia V. Leiva (20114264)

“…Survival and longevity were significantly higher at lower temperature and copper concentration (14°C and 0.2 mg/L). …”

Ranking of factors in order of importance as reported by survey respondents regarding the difficulty in accessing the lower uterine segment (A), complicated fetal extraction in ces... by María Jesús Cancelo Hidalgo (12154030)

Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Study selection criteria. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

Subjects: